Press Releases
Media Contact:
Lorie Calvo
425-608-3008
Successful £15 million Fundraising and First Day of Dealings on AIM
Northwest Biotherapeutics, Inc. (AIM: NWBT and NWBS; OTC BB: NWBT.US), the US based biotechnology company focused on the clinical development of immunotherapy products for cancer, today announces that it has raised £15 million (before expenses) via a Placing and that trading in Northwest shares will commence on the London Stock Exchange’s AIM market today at 8:00 a.m.
Collins Stewart Europe Limited is acting as Nominated Adviser and Broker to the Company.
For further information, please contact:
Northwest Biotherapeutics
Alton Boynton, President and Chief Executive Officer |
+ 1 240 497 9021
+1 425 608 3008 |
Buchanan Communications
Lisa Baderoon (lisab@buchanan.uk.com)
/ Mary-Jane Johnson / Catherine Breen
|
+44 (0)20 7466 5000
|
Collins Stewart
Tim Mickley
Adam Cowen |
+44 (0)20 7523 8313
+44 (0)20 7523 8320 |
This announcement is not for distribution, directly or indirectly, in or into the United States. This announcement is not an offer of securities for sale in or into the United States or any other jurisdiction. Securities may not be offered or sold in the United States (as such term is defined in Regulation S under the US Securities Act of 1933, as amended) unless they are registered or exempt from registration under the US Securities Act of 1933, as amended. There will be no registration of any portion of the shares offered in the placing in the United States and no offer of securities in the United States. A copy of this announcement is not being, and should not be, distributed in or sent into the United States.
|
